Acute pancreatitis resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(19 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}} {{AE}} {{VB}}
{{CMG}}; {{AE}} {{VB}}; {{VR}}


==Definition==
==Overview==
Acute pancreatitis is an acute inflammation of the [[pancreas]].
Acute pancreatitis is the acute inflammation of the [[pancreas]].


==Diagnostic Criteria==
==Diagnostic Criteria==
▸ Diagnosis is established by the presence of two of the three following criteria ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]):<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
▸ Diagnosis is established by the presence of two of the three following criteria ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]):<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back).'''
* '''Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back)'''
<!--
<!--
::* A dull, colicky pain located in the lower abdomen suggests an alternative etiology.
::* A dull, colicky pain located in the lower abdomen suggests an alternative etiology.
-->
-->
* '''Serum [[lipase]] or [[amylase]] ≥ 3 x ULN.'''
* '''Serum [[lipase]] or [[amylase]] ≥ 3 x ULN'''
<!--
<!--
::* Amylase may be falsely elevated in [[appendicitis]], [[cholecystitis]], [[intestinal obstruction]] or [[Mesenteric ischemia|ischemia]], [[perforated ulcer]], [[salivary gland]] disease, gynecological disease, renal disease, and [[macroamylasemia]].
::* Amylase may be falsely elevated in [[appendicitis]], [[cholecystitis]], [[intestinal obstruction]] or [[Mesenteric ischemia|ischemia]], [[perforated ulcer]], [[salivary gland]] disease, gynecological disease, renal disease, and [[macroamylasemia]].
Line 17: Line 17:
::* Lipase may be falsely elevated in [[appendicitis]], [[cholecystitis]], renal disease, and macrolipasemia.
::* Lipase may be falsely elevated in [[appendicitis]], [[cholecystitis]], renal disease, and macrolipasemia.
-->
-->
* '''Characteristic findings on contrast-enhanced [[computed tomography|CT]], [[magnetic resonance imaging|MRI]], or transabdominal [[ultrasonography|US]].'''
* '''Characteristic findings on contrast-enhanced computed tomography (CECT), [[magnetic resonance imaging|MRI]], or transabdominal [[ultrasonography|US]]'''
<!--
<!--
::* If abdominal pain strongly suggests acute pancreatitis but pancreatic enzyme is less than three times the upper limit of normal, a confirmatory imaging is required.<ref name="Bollen-2007">{{Cite journal  | last1 = Bollen | first1 = TL. | last2 = van Santvoort | first2 = HC. | last3 = Besselink | first3 = MG. | last4 = van Es | first4 = WH. | last5 = Gooszen | first5 = HG. | last6 = van Leeuwen | first6 = MS. | title = Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. | journal = Semin Ultrasound CT MR | volume = 28 | issue = 5 | pages = 371-83 | month = Oct | year = 2007 | doi =  | PMID = 17970553 }}</ref><ref name="Morgan-2008">{{Cite journal  | last1 = Morgan | first1 = DE. | title = Imaging of acute pancreatitis and its complications. | journal = Clin Gastroenterol Hepatol | volume = 6 | issue = 10 | pages = 1077-85 | month = Oct | year = 2008 | doi = 10.1016/j.cgh.2008.07.012 | PMID = 18928934 }}</ref>
::* If abdominal pain strongly suggests acute pancreatitis but pancreatic enzyme is less than three times the upper limit of normal, a confirmatory imaging is required.<ref name="Bollen-2007">{{Cite journal  | last1 = Bollen | first1 = TL. | last2 = van Santvoort | first2 = HC. | last3 = Besselink | first3 = MG. | last4 = van Es | first4 = WH. | last5 = Gooszen | first5 = HG. | last6 = van Leeuwen | first6 = MS. | title = Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. | journal = Semin Ultrasound CT MR | volume = 28 | issue = 5 | pages = 371-83 | month = Oct | year = 2007 | doi =  | PMID = 17970553 }}</ref><ref name="Morgan-2008">{{Cite journal  | last1 = Morgan | first1 = DE. | title = Imaging of acute pancreatitis and its complications. | journal = Clin Gastroenterol Hepatol | volume = 6 | issue = 10 | pages = 1077-85 | month = Oct | year = 2008 | doi = 10.1016/j.cgh.2008.07.012 | PMID = 18928934 }}</ref>
::* If the diagnosis is established by abdominal pain and elevated pancreatic enzyme, a CECT is not usually required on admission.
::* If the diagnosis is established by abdominal pain and elevated pancreatic enzyme, a CECT is not usually required on admission.
-->
-->
==Types==
* '''Interstitial Edematous Pancreatitis'''
:▸ Acute inflammation of the pancreatic parenchyma and peripancreatic tissues, but without recognizable tissue necrosis.
:: ''CECT criteria''
::▸ Pancreatic parenchyma enhancement by intravenous contrast agent. <BR>
::▸ No findings of peripancreatic necrosis.
* '''Necrotizing Pancreatitis'''
:▸ Inflammation associated with pancreatic parenchymal necrosis and/or peripancreatic necrosis.
:: ''CECT criteria''
::▸ Lack of pancreatic parenchymal enhancement by intravenous contrast agent. <BR>
::▸ Presence of findings of peripancreatic necrosis.
* '''Infected Pancreatic Necrosis''':
:▸ Should be considered in patients with necrotizing pancreatitis who deteriorate or fail to improve after 7–10 days of hospitalization.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen |first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. |last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
:▸ May be presumed by the presence of extraluminal gas on CECT or when fine-needle aspiration is positive for bacteria and/or fungi on Gram stain and culture.<ref name="Banks-1995">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Gerzof | first2 = SG. | last3 = Langevin | first3 = RE. | last4 = Silverman | first4 = SG. | last5 = Sica | first5 = GT. | last6 = Hughes | first6 = MD. | title = CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. | journal = Int J Pancreatol | volume = 18 | issue = 3 | pages = 265-70 | month = Dec | year = 1995 | doi = 10.1007/BF02784951 | PMID = 8708399 }}</ref>
:▸ Antibiotics able to penetrate pancreatic necrosis (such as [[carbapenem]]s, [[quinolone]]s, and [[metronidazole]]) may be useful in delaying or sometimes totally avoiding intervention.<ref name="Petrov-2010">{{Cite journal  | last1 = Petrov | first1 = MS. | last2 = Shanbhag | first2 = S. | last3 = Chakraborty | first3 = M. | last4 = Phillips | first4 = AR. | last5 = Windsor | first5 = JA. | title = Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. | journal = Gastroenterology | volume = 139 | issue = 3 | pages = 813-20 | month = Sep | year = 2010 | doi = 10.1053/j.gastro.2010.06.010 | PMID = 20540942 }}</ref><ref name="van Santvoort-2011">{{Cite journal  | last1 = van Santvoort | first1 = HC. | last2 = Bakker | first2 = OJ. | last3 = Bollen | first3 = TL. | last4 = Besselink | first4 = MG. | last5 = Ahmed Ali | first5 = U. | last6 = Schrijver | first6 = AM. | last7 = Boermeester | first7 = MA. | last8 = van Goor | first8 = H. | last9 = Dejong | first9 = CH. | title = A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. | journal = Gastroenterology | volume = 141 | issue = 4 | pages = 1254-63 | month = Oct | year = 2011 | doi = 10.1053/j.gastro.2011.06.073 | PMID = 21741922 }}</ref>
==Complications==
===Organ Failure===
* '''''Modified Marshall Scoring System'''''
{| {{table}}
|+ '''Modified Marshall Scoring System<sup>†</sup>'''
| align="left" width=200px style="background:#f0f0f0;"|'''Organ System'''
| align="left" width=150px style="background:#f0f0f0;"|'''0'''
| align="left" width=150px style="background:#f0f0f0;"|'''1'''
| align="left" width=150px style="background:#f0f0f0;"|'''2'''
| align="left" width=150px style="background:#f0f0f0;"|'''3'''
| align="left" width=150px style="background:#f0f0f0;"|'''4'''
|-
| valign="bottom" width=200px | '''Respiratory''' <BR> PaO2/FiO2
| valign="bottom" width=150px | >400
| valign="bottom" width=150px | 301-400
| valign="bottom" width=150px | 201-300
| valign="bottom" width=150px | 101-200
| valign="bottom" width=150px | ≤101
|-
| valign="bottom" width=200px | '''Renal<sup>‡</sup>''' <BR> Creatinine (μmol/l) <BR> Creatinine (mg/dl)
| valign="bottom" width=150px | ≤134 <BR> <1.4
| valign="bottom" width=150px | 134-169 <BR> 1.4-1.8
| valign="bottom" width=150px | 170-310 <BR> 1.9-3.6
| valign="bottom" width=150px | 311-439 <BR> 3.6-4.9
| valign="bottom" width=150px | >439 <BR> >4.9
|-
| valign="bottom" width=200px | '''Cardiovascular''' <BR> Systolic Blood Pressure (mmHg)
| valign="bottom" width=150px | >90
| valign="bottom" width=150px | <90, fluid responsive
| valign="bottom" width=150px | <90, not fluid responsive
| valign="bottom" width=150px | <90, pH <7.3
| valign="bottom" width=150px | <90, pH <7.2
|-
|}
<sup>†</sup> A score of 2 or more in any system defines the presence of organ failure. <BR>
<sup>‡</sup> A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.
▸ ''For non-ventilated patients, the FiO2 can be estimated from below:''
{| {{table}}
| align="center" style="background:#f0f0f0;"|'''Supplemental oxygen (l/min)'''
| align="center" style="background:#f0f0f0;"|'''FiO2 (%)'''
|-
| Room air||21
|-
| 2||25
|-
| 4||30
|-
| 6–8 ||40
|-
| 9–10||50
|}
* '''Transient organ failure''' = organ failure resolves within 48 h.
* '''Persistent organ failure''' = organ failure persists for >48 h.<ref name="Johnson-2004">{{Cite journal  | last1 = Johnson | first1 = CD. | last2 = Abu-Hilal | first2 = M. | title = Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. | journal = Gut | volume = 53 | issue = 9 | pages = 1340-4 | month = Sep | year = 2004 | doi = 10.1136/gut.2004.039883 | PMID = 15306596 }}</ref><ref name="Mofidi-2006">{{Cite journal  | last1 = Mofidi | first1 = R. | last2 = Duff | first2 = MD. | last3 = Wigmore | first3 = SJ. | last4 = Madhavan | first4 = KK. | last5 = Garden | first5 = OJ. | last6 = Parks | first6 = RW. | title = Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. | journal = Br J Surg | volume = 93 | issue = 6 | pages = 738-44 | month = Jun | year = 2006 | doi = 10.1002/bjs.5290 | PMID = 16671062 }}</ref><ref name="Lytras-2008">{{Cite journal  | last1 = Lytras | first1 = D. | last2 = Manes | first2 = K. | last3 = Triantopoulou | first3 = C. | last4 = Paraskeva | first4 = C. | last5 = Delis | first5 = S. | last6 = Avgerinos | first6 = C. | last7 = Dervenis | first7 = C. | title = Persistent early organ failure: defining the high-risk group of patients with severe acute pancreatitis? | journal = Pancreas | volume = 36 | issue = 3 | pages = 249-54 | month = Apr | year = 2008 | doi = 10.1097/MPA.0b013e31815acb2c | PMID = 18362837 }}</ref>
===Local Complications===
▸ Should be suspected when there is persistence/recurrence of abdominal pain, secondary increases in pancreatic enzyme, increasing organ dysfunction, or the development of signs of [[sepsis]].<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen| first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen |first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. |last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Acute Peripancreatic Fluid Collection (APFC)'''
:▸ Peripancreatic fluid associated with interstitial edematous pancreatitis with no associated peripancreatic necrosis. This term applies only to areas of peripancreatic fluid seen within the first 4 weeks after onset of interstitial edematous pancreatitis and without the features of a pseudocyst.
:: ''CECT criteria''
::▸ Occurs in the setting of interstitial edematous pancreatitis. <BR>
::▸ Homogeneous collection with fluid density. <BR>
::▸ Confined by normal peripancreatic fascial planes. <BR>
::▸ No definable wall encapsulating the collection. <BR>
::▸ Adjacent to pancreas (no intrapancreatic extension).
* '''Pancreatic Pseudocyst'''
:▸ An encapsulated collection of fluid with a well defined inflammatory wall usually outside the pancreas with minimal or no necrosis. This entity usually occurs more than 4 weeks after onset of interstitial edematous pancreatitis to mature.
:: ''CECT criteria''
::▸ Well circumscribed, usually round or oval. <BR>
::▸ Homogeneous fluid density. <BR>
::▸ No non-liquid component. <BR>
::▸ Well defined wall; that is, completely encapsulated. <BR>
::▸ Maturation usually requires >4 weeks after onset of acute pancreatitis; occurs after interstitial edematous pancreatitis.
* '''Acute necrotic collection (ANC)'''
:▸ A collection containing variable amounts of both fluid and necrosis associated with necrotizing pancreatitis; the necrosis can involve the pancreatic parenchyma and/or the peripancreatic tissues.
:: ''CECT criteria''
::▸ Occurs only in the setting of acute necrotising pancreatitis. <BR>
::▸ Heterogeneous and non-liquid density of varying degrees in different locations (some appear homogeneous early in their course). <BR>
::▸ No definable wall encapsulating the collection. <BR>
::▸ Location—intrapancreatic and/or extrapancreatic.
* '''Walled-off necrosis (WON)'''
:▸ A mature, encapsulated collection of pancreatic and/or peripancreatic necrosis that has developed a well defined inflammatory wall. WON usually occurs >4 weeks after onset of necrotising pancreatitis.
:: ''CECT criteria''
::▸ Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear homogeneous). <BR>
::▸ Well defined wall, that is, completely encapsulated. <BR>
::▸ Location—intrapancreatic and/or extrapancreatic. <BR>
::▸ Maturation usually requires 4 weeks after onset of acute necrotizing pancreatitis
===Systemic Complications===
▸ Defined as exacerbation of pre-existing co-morbidity, such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis.
==Grades of Severity==
The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Mild acute pancreatitis'''
: ▸ No organ failure
: ▸ No local or systemic complications
* '''Moderately severe acute pancreatitis'''
: ▸ Organ failure that resolves within 48 h (transient organ failure) and/or
: ▸ Local or systemic complications without persistent organ failure
* '''Severe acute pancreatitis'''
: ▸ Persistent organ failure (>48 h)
: – Single organ failure
: – Multiple organ failure


==Causes==
==Causes==
===Life Threatening Causes===
===Life Threatening Causes===
''Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.''
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Acute pancreatitis is a life-threatening condition, especially if it progresses to necrotizing pancreatitis, and should be treated as such irrespective of the cause.
 
Acute pancreatitis from any cause may be life-threatening especially if it progresses to necrotizing pancreatitis.


===Common Causes===
===Common Causes===
Line 157: Line 34:
* [[Hypertriglyceridemia]] 1-4% cases <ref name="Fortson-1995">{{Cite journal  | last1 = Fortson | first1 = MR. | last2 = Freedman | first2 = SN. | last3 = Webster | first3 = PD. | title = Clinical assessment of hyperlipidemic pancreatitis. | journal = Am J Gastroenterol | volume = 90 | issue = 12 | pages = 2134-9 | month = Dec | year = 1995 | doi =  | PMID = 8540502 }}</ref>
* [[Hypertriglyceridemia]] 1-4% cases <ref name="Fortson-1995">{{Cite journal  | last1 = Fortson | first1 = MR. | last2 = Freedman | first2 = SN. | last3 = Webster | first3 = PD. | title = Clinical assessment of hyperlipidemic pancreatitis. | journal = Am J Gastroenterol | volume = 90 | issue = 12 | pages = 2134-9 | month = Dec | year = 1995 | doi =  | PMID = 8540502 }}</ref>


* Medication such as [[5-mercaptopurine]], [[azathioprine]], [[5-DDI]]<ref name="Yi-2012">{{Cite journal  | last1 = Yi | first1 = GC. | last2 = Yoon | first2 = KH. | last3 = Hwang | first3 = JB. | title = Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease. | journal = Pediatr Gastroenterol Hepatol Nutr | volume = 15 | issue = 4 | pages = 272-5 | month = Dec | year = 2012 | doi = 10.5223/pghn.2012.15.4.272 | PMID = 24010098 }}</ref>
* Medication such as [[mercaptopurine|5-mercaptopurine]], [[azathioprine]], [[5-DDI]]<ref name="Yi-2012">{{Cite journal  | last1 = Yi | first1 = GC. | last2 = Yoon | first2 = KH. | last3 = Hwang | first3 = JB. | title = Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease. | journal = Pediatr Gastroenterol Hepatol Nutr | volume = 15 | issue = 4 | pages = 272-5 | month = Dec | year = 2012 | doi = 10.5223/pghn.2012.15.4.272 | PMID = 24010098 }}</ref>


* [[Pancreatic tumor]]<ref name="Köhler-1987">{{Cite journal  | last1 = Köhler | first1 = H. | last2 = Lankisch | first2 = PG. | title = Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma. | journal = Pancreas | volume = 2 | issue = 1 | pages = 117-9 | month =  | year = 1987 | doi =  | PMID = 2437571 }}</ref>
* [[Pancreatic tumor]]<ref name="Köhler-1987">{{Cite journal  | last1 = Köhler | first1 = H. | last2 = Lankisch | first2 = PG. | title = Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma. | journal = Pancreas | volume = 2 | issue = 1 | pages = 117-9 | month =  | year = 1987 | doi =  | PMID = 2437571 }}</ref>


* Post - [[ERCP]]
* [[ERCP|Post-ERCP]]


==Management==
==Management==
Line 167: Line 44:


{{familytree/start |summary=Acute Pancreatitis}}
{{familytree/start |summary=Acute Pancreatitis}}
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms:''' <br> ❑ Severe abdominal pain and/or <br> ❑ Breathing difficulty and/or <br> ❑ Nausea & vomiting and/or <br> ❑ Hiccups sometimes </div> }}
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms:''' <br> ❑ Severe abdominal pain <br> ❑ Breathing difficulty <br> ❑ Nausea & vomiting <br> ❑ Hiccups sometimes </div> }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | A11 | | | | | | | | | | | | | | |A11=<div style="float: left; text-align: left; line-height: 150% ">'''Examine the patient:''' <br> ❑ Fever and/or <br> ❑ Hypotension and/or <br> ❑ [[Cullen's sign]] and/or <br> ❑ [[Grey-Turner's sign]] and/or <br> ❑  Tachypnea and/or <br> ❑ Abdominal distension and/or tenderness</div>}}
{{familytree | | | | | | | | | | | | | A11 | | | | | | | | | | | | | | |A11=<div style="float: left; text-align: left; line-height: 150% ">'''Examine the patient:''' <br> ❑ Fever<br> ❑ Hypotension <br> ❑ [[Cullen's sign]]<br> ❑ [[Grey-Turner's sign]]<br> ❑  Tachypnea<br> ❑ Abdominal distension and/or tenderness</div>}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | A12 | | | | | | | | | | | | | | |A12=<div style="float: left; text-align: left; line-height: 150% ">'''Consider alternative diagnosis:''' <br> ❑ [[Gallstones]] <br> ❑ [[Dissecting aortic aneurysm]] <br> ❑ [[Pancreatic pseudocyst]] </div> }}
{{familytree | | | | | | | | | | | | | A12 | | | | | | | | | | | | | | |A12=<div style="float: left; text-align: left; line-height: 150% ">'''Consider alternative diagnosis:''' <br> ❑ [[Gallstones]] <br> ❑ [[Dissecting aortic aneurysm]] <br> ❑ [[Pancreatic pseudocyst]] </div> }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | E01 |-|-|-|-|-|-|.| | |E01=Hemodynamic stability? }}
{{familytree | | | | | | | | | | | | | E01 |-|-|-|-|-|-|.| | |E01=❑ Assess hemodynamic stability }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | |!| |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | |!| |}}
{{familytree | | | | | | | | | | | | | Z01 | | | | | | Z02 | | | | |Z01 = Stable|Z02= Unstable|border=0 }}  
{{familytree | | | | | | | | | | | | | Z01 | | | | | | Z02 | | | | |Z01 = Stable|Z02= Unstable|border=0 }}  
Line 185: Line 62:
{{familytree | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria: Any 2 out of 3''' <br> ❑  Abdominal pain consistent with disease<br> ❑ Serum amylase or lipase values > 3 times normal <br> ❑ Consistent findings from abdominal imaging </div>}}
{{familytree | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria: Any 2 out of 3''' <br> ❑  Abdominal pain consistent with disease<br> ❑ Serum amylase or lipase values > 3 times normal <br> ❑ Consistent findings from abdominal imaging </div>}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | |D01=Acute Pancreatitis}}
{{familytree | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | |D01='''Acute Pancreatitis'''}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | F01 |-|-|-|-|-| F02 |-|.| | | | |F01=[[Systemic inflammatory response syndrome]]? '''(Urgent)''' |F02=Yes|"border=0" }}
{{familytree | | | | | | | | | | | | | F01 |-|-|-|-|-| F02 |-|.| | | | |F01=[[Systemic inflammatory response syndrome]]? '''(Urgent)''' |F02=Yes|"border=0" }}
Line 191: Line 68:
{{familytree |border=0 | | | | | | | | | | | | | AA1 | | | | | | | | | |!| | | | |AA1=No}}
{{familytree |border=0 | | | | | | | | | | | | | AA1 | | | | | | | | | |!| | | | |AA1=No}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | | |}}
{{familytree | | | | | | | | | | | | | G01 | | | | | | | | | |!| | | | |G01=Risk stratification (Marshall scoring)'''(Urgent)'''}}
{{familytree | | | | | | | | | | | | | G01 | | | | | | | | | |!| | | | |G01=Risk stratification for organ failure<br> ([[Gallstone pancreatitis resident survival guide#Modified Marshall Scoring System|Marshall scoring]]) '''(Urgent)'''}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | |!| | | | |}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | |!| | | | |}}
{{familytree | | | | | | H01 | | | | | | | | | | | | H02 | | |!| | | | |H01=Lower risk |H02=Higher risk}}
{{familytree | | | | | | H01 | | | | | | | | | | | | H02 | | |!| | | | |H01=Lower risk |H02=Higher risk}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | |!| | | | |}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | |!| | | | |}}
{{familytree | | | | | | I01 | | | | | | | | | | | | I02 |-|-|'| | | | |I01=Admit to medical ward |I02=Admit to ICU '''(Urgent)'''}}
{{familytree | | | | | | I01 | | | | | | | | | | | | I02 |-|-|'| | | | |I01=Admit to medical ward |I02=Admit to ICU '''(Urgent)'''}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | J01 | | | | | | | | | | | | J02 | | | | | | | |J01=<div style="float: left; text-align: left; line-height: 150% "> '''Fluids: (Urgent)''' <br><br> ❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs <br> ❑ Reassess within 6 hrs after admission and for next 24-48 hrs
{{familytree | | | | | | J01 | | | | | | | | | | | | J02 | | | | | | | |J01=<div style="float: left; text-align: left; line-height: 150% "> '''Fluids: (Urgent)''' <br><br> ❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs <br> ❑ Reassess within 6 hrs after admission and for next 24-48 hrs
Line 208: Line 85:
'''Nutrition: (Urgent)'''  <br> ❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside <br> ❑ Consider enteral feeding if above not tolerated </div>}}
'''Nutrition: (Urgent)'''  <br> ❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside <br> ❑ Consider enteral feeding if above not tolerated </div>}}
{{familytree | | | | | | |`|-|-|-|-|-|-|v|-|-|-|-|-|-|'| | | | | | | | |}}
{{familytree | | | | | | |`|-|-|-|-|-|-|v|-|-|-|-|-|-|'| | | | | | | | |}}
{{familytree | | | | | | | | | | | | | K01 |-|-|-|-|-| K02 |-|-|-|-| K03 |K01=Cholangitis or biliary obstruction |K02=Yes |K03=ERCP within 24 hrs/Cholecystectomy to prevent recurrence }}
{{familytree | | | | | | | | | | | | | K01 |-|-|-|-|-| K02 |-|-|-|-| K03 |K01='''Cholangitis or biliary obstruction''' |K02=Yes |K03=ERCP within 24 hrs/Cholecystectomy to prevent recurrence<br> Click '''[[gallstone pancreatitis resident survival guide|here]]''' for more details}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AK1 | | | | | | | | |AK1=No | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AK1 | | | | | | | | |AK1=No | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | L01 | | | | | | | | | | | | | | |L01=Consider MRCP/EUS}}
{{familytree | | | | | | | | | | | | | L01 | | | | | | | | | | | | | | |L01=Consider MRCP/EUS}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | M01 |-|-|-|-|-| M02 |-|-|-|-| M03 | | | | | |M01=Clinical improvement within 48-72 hrs |M02=Yes |M03=Assess for ability to maintain oral feeding at the end of 1 week}}
{{familytree | | | | | | | | | | | | | M01 |-|-|-|-|-| M02 |-|-|-|-| M03 | | | | | |M01=Clinical improvement within 48-72 hrs |M02=Yes |M03=Assess for ability to maintain oral feeding at the end of 1 week}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | }}
{{familytree |border=0 | | | | | | | | | | | | | AE1 | | | |AE1=N o  | | | | | | | | | | |!|}}
{{familytree |border=0 | | | | | | | | | | | | | AE1 | | | |AE1=N o  | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | N01 | | | | | | | | | | | | | N02 | | | | |N01=CECT/MRI |N02=Recovery}}
{{familytree | | | | | | | | | | | | | N01 | | | | | | | | | | | | | N02 | | | | |N01=CECT/MRI |N02=Recovery}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | O01 | | | | | | | | | | | | | | |O01=Pancreatic necrosis}}
{{familytree | | | | | | | | | | | | | O01 | | | | | | | | | | | | | | |O01='''Pancreatic necrosis'''}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | P01 |-|-|-|-|-| P02 |-|-|-|-| P03 |P01=Failure to improve clinically after 7-10 days of hospitalization|P02=Yes|P03=Supportive treatment|}}
{{familytree | | | | | | | | | | | | | P01 |-|-|-|-|-| P02 |-|-|-|-| P03 |P01=Failure to improve clinically after 7-10 days of hospitalization|P02=Yes|P03=Supportive treatment|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | || | AF1 | | | | |AF1=No | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AF1 | | | | |AF1=No | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | Q01 | | | | | | | | | | | | | | |Q01=Suspect Infected necrosis}}
{{familytree | | | | | | | | | | | | | Q01 | | | | | | | | | | | | | | |Q01=Suspected infected necrosis}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | R01 |-|-|-|-| R02 |-|-|-|-| R03 |R01=<div style="float: left; text-align: left; line-height: 150% "> <br> ❑ CT guided FNA  
{{familytree | | | | | | | | | | | | | R01 |-|-|-|-| R02 |-|-|-|-| R03 |R01=<div style="float: left; text-align: left; line-height: 150% "> <br> ❑ CT guided FNA  
Line 236: Line 113:
{{familytree |border=0 | | | | | | | | | | | | | |  AG1  | | | | | | |AG1=Gram stain & Culture(+) | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | |  AG1  | | | | | | |AG1=Gram stain & Culture(+) | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | S01 | | | | | | | | | | | | | | |S01=Infected necrosis}}
{{familytree | | | | | | | | | | | | | S01 | | | | | | | | | | | | | | |S01='''Infected necrosis'''}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | |}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | |}}
{{familytree | | | | | | T01 | | | | | | | | | | | | T02 | | | | | | | |T01=Clinically stable|T02=Clinically unstable}}
{{familytree | | | | | | T01 | | | | | | | | | | | | T02 | | | | | | | |T01=Clinically stable|T02=Clinically unstable}}
Line 243: Line 120:
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree/end}}
{{familytree/end}}
<sup>†</sup>'''ALT:''' Alanine aminotransferase; '''AST:''' Aspartate aminotransferase; '''BUN:''' Blood urea nitrogen; '''CBC:''' Complete blood count; '''CECT:''' Contrast-enhanced computed tomography; '''CT:''' Computed tomography; '''ERCP:''' Endoscopic retrograde cholangiopancreatography; '''EU:''' Endoscopic ultrasound; '''FNA:''' Fine-needle aspiration; '''GGT:''' Gamma-glutamyl transpeptidase; '''ICU''': Intensive care unit; '''IV:''' Intravenous; '''MRCP:''' Magnetic resonance cholangiopancreatography; '''MRI:''' Magnetic resonance imaging; '''Q8h:''' Every 8 hours; '''Q12h:''' Every 12 hours
 
<span style="font-size:85%">'''ALT:''' Alanine aminotransferase; '''AST:''' Aspartate aminotransferase; '''BUN:''' Blood urea nitrogen; '''CBC:''' Complete blood count; '''CECT:''' Contrast-enhanced computed tomography; '''CT:''' Computed tomography; '''ERCP:''' Endoscopic retrograde cholangiopancreatography; '''EU:''' Endoscopic ultrasound; '''FNA:''' Fine-needle aspiration; '''GGT:''' Gamma-glutamyl transpeptidase; '''ICU''': Intensive care unit; '''IV:''' Intravenous; '''MRCP:''' Magnetic resonance cholangiopancreatography; '''MRI:''' Magnetic resonance imaging; '''Q8h:''' Every 8 hours; '''Q12h:''' Every 12 hours </span>
 
==Modified Marshall Scoring System==
{| {{table}}
|+ '''Modified Marshall Scoring System<sup>†</sup>'''
| align="left" width=200px style="background:#f0f0f0;"|'''Organ System'''
| align="left" width=150px style="background:#f0f0f0;"|'''0'''
| align="left" width=150px style="background:#f0f0f0;"|'''1'''
| align="left" width=150px style="background:#f0f0f0;"|'''2'''
| align="left" width=150px style="background:#f0f0f0;"|'''3'''
| align="left" width=150px style="background:#f0f0f0;"|'''4'''
|-
| valign="bottom" width=200px | '''Respiratory''' <BR> PaO2/FiO2
| valign="bottom" width=150px | >400
| valign="bottom" width=150px | 301-400
| valign="bottom" width=150px | 201-300
| valign="bottom" width=150px | 101-200
| valign="bottom" width=150px | ≤101
|-
| valign="bottom" width=200px | '''Renal<sup>‡</sup>''' <BR> Creatinine (μmol/l) <BR> Creatinine (mg/dl)
| valign="bottom" width=150px | ≤134 <BR> <1.4
| valign="bottom" width=150px | 134-169 <BR> 1.4-1.8
| valign="bottom" width=150px | 170-310 <BR> 1.9-3.6
| valign="bottom" width=150px | 311-439 <BR> 3.6-4.9
| valign="bottom" width=150px | >439 <BR> >4.9
|-
| valign="bottom" width=200px | '''Cardiovascular''' <BR> Systolic Blood Pressure (mmHg)
| valign="bottom" width=150px | >90
| valign="bottom" width=150px | <90, fluid responsive
| valign="bottom" width=150px | <90, not fluid responsive
| valign="bottom" width=150px | <90, pH <7.3
| valign="bottom" width=150px | <90, pH <7.2
|-
|}
<sup>†</sup> A score of 2 or more in any system defines the presence of organ failure. <BR>
<sup>‡</sup> A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.
 
▸ ''For non-ventilated patients, the FiO2 can be estimated from below:''
{| {{table}}
| align="center" style="background:#f0f0f0;"|'''Supplemental oxygen (l/min)'''
| align="center" style="background:#f0f0f0;"|'''FiO2 (%)'''
|-
| Room air||21
|-
| 2||25
|-
| 4||30
|-
| 6–8 ||40
|-
| 9–10||50
|}
 
==Grades of Severity==
The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
 
* '''Mild acute pancreatitis'''
: ▸ No organ failure
: ▸ No local or systemic complications
* '''Moderately severe acute pancreatitis'''
: ▸ Organ failure that resolves within 48 h (transient organ failure) and/or
: ▸ Local or systemic complications without persistent organ failure
* '''Severe acute pancreatitis'''
: ▸ Persistent organ failure (>48 h)
: – Single organ failure
: – Multiple organ failure


==Do's==
==Do's==
Line 259: Line 202:
*Administer a rapid bolus in patient's with hypotension and tachycardia ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Administer a rapid bolus in patient's with hypotension and tachycardia ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Use [[Lactated Ringer's solution|Ringer's Lactate(RL)]] as first choice agent, use [[normal saline]] if RL not available ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Use [[Lactated Ringer's solution|Ringer's Lactate(RL)]] as first choice agent, use [[normal saline]] if RL not available ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Do ERCP within 24 hours of admission in patients with acute pancreatitis and concurrent acute cholangitis ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]).  In its absence, MRCP or EUS should be used for screening choledocholithiasis if highly suspected ([[GRADE system classification scheme|conditional recommendation, low quality of evidence).  
*Do ERCP within 24 hours of admission in patients with acute pancreatitis and concurrent acute cholangitis ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]).  In its absence, MRCP or EUS should be used for screening choledocholithiasis if highly suspected ([[GRADE system classification scheme|conditional recommendation, low quality of evidence]]).
*Do consider the diagnosis of gallstone pancreatitis in patients with previous history of biliary colic or gallbladder related symptoms, elevated ALT, elevated AST and gallstones detected during ultrasound and for further management, please click '''[[Sandbox RSG:Gallstone pancreatitis|here]]'''. 
*Pancreatic duct stents or post-procedure NSAID's are recommended to prevent post-ERCP pancreatitis ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Pancreatic duct stents or post-procedure NSAID's are recommended to prevent post-ERCP pancreatitis ([[GRADE system classification scheme|conditional recommendation, moderate quality of evidence]]).
*Antibiotics are given for extra-pancreatic infections such as [[cholangitis]], [[catheter-acquired infections]], [[bacteremia]], [[UTI|UTI's]], [[pneumonia]] ([[GRADE system classification scheme|strong recommendation, high quality of evidence]]).  
*Antibiotics are given for extra-pancreatic infections such as [[cholangitis]], [[catheter-acquired infections]], [[bacteremia]], [[UTI|UTI's]], [[pneumonia]] ([[GRADE system classification scheme|strong recommendation, high quality of evidence]]).  

Latest revision as of 00:13, 13 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]

Overview

Acute pancreatitis is the acute inflammation of the pancreas.

Diagnostic Criteria

▸ Diagnosis is established by the presence of two of the three following criteria (strong recommendation, moderate quality of evidence):[1]

  • Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back)
  • Serum lipase or amylase ≥ 3 x ULN
  • Characteristic findings on contrast-enhanced computed tomography (CECT), MRI, or transabdominal US

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Acute pancreatitis is a life-threatening condition, especially if it progresses to necrotizing pancreatitis, and should be treated as such irrespective of the cause.

Common Causes

Management

Shown below is a diagram depicting the management of acute pancreatitis according to the American College of Gastroenterology (ACG).[7]

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Severe abdominal pain
❑ Breathing difficulty
❑ Nausea & vomiting
❑ Hiccups sometimes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Fever
❑ Hypotension
Cullen's sign
Grey-Turner's sign
❑ Tachypnea
❑ Abdominal distension and/or tenderness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
Gallstones
Dissecting aortic aneurysm
Pancreatic pseudocyst
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess hemodynamic stability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable
 
 
 
 
 
Unstable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order Labs: (Urgent)
CBC
Hematocrit
BUN
Creatinine
Amylase
Lipase
Triglyceride
❑ Total bilirubin
❑ Direct bilirubin
Albumin
AST
ALT
Alkaline phosphatase
GGT
Chest X-ray
Order imaging studies: (Urgent)
Trans abdominal USG (TAUSG)
 
 
 
 
 
Stabilize the patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic criteria: Any 2 out of 3
❑ Abdominal pain consistent with disease
❑ Serum amylase or lipase values > 3 times normal
❑ Consistent findings from abdominal imaging
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute Pancreatitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemic inflammatory response syndrome? (Urgent)
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk stratification for organ failure
(Marshall scoring) (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lower risk
 
 
 
 
 
 
 
 
 
 
 
Higher risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Admit to medical ward
 
 
 
 
 
 
 
 
 
 
 
❑ Admit to ICU (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluids: (Urgent)

❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs
❑ Reassess within 6 hrs after admission and for next 24-48 hrs

Analgesics: (Urgent)

❑ Opioids are preferred
❑ Mepridine & morphine may be used as IV drips/pt. controlled analgesia


Nutrition: (Urgent)

❑ Immediate oral feeding as soon as pain, vomiting, nausea subside
 
 
 
 
 
 
 
 
 
 
 
Fluids: (Urgent)
❑ Initiate with a fluid bolus
❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs
❑ Reassess within 6 hrs after admission and for next 24-48 hrs

Analgesics: (Urgent)
❑ Opioids are preferred
❑ Mepridine & morphine may be used as IV drips/pt. controlled analgesia


Nutrition: (Urgent)
❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside
❑ Consider enteral feeding if above not tolerated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cholangitis or biliary obstruction
 
 
 
 
 
Yes
 
 
 
 
❑ ERCP within 24 hrs/Cholecystectomy to prevent recurrence
Click here for more details
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Consider MRCP/EUS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical improvement within 48-72 hrs
 
 
 
 
 
Yes
 
 
 
 
❑ Assess for ability to maintain oral feeding at the end of 1 week
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ CECT/MRI
 
 
 
 
 
 
 
 
 
 
 
 
Recovery
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pancreatic necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Failure to improve clinically after 7-10 days of hospitalization
 
 
 
 
 
Yes
 
 
 
 
❑ Supportive treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspected infected necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ CT guided FNA

❑ Empiric antibiotics, necrosis penetrating:

❑ Meropenem 1g IV Q8h
❑ Ciprofloxacin 400mg IV Q12h plus metronidazole 500 mg IV Q8h for 14 days
 
 
 
 
Gram stain & Culture (-)
 
 
 
 
❑ Supportive treatment
❑ Consider repeat CT FNA every 7 days if no improvement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gram stain & Culture(+)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infected necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinically stable
 
 
 
 
 
 
 
 
 
 
 
Clinically unstable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Continue antibiotics & observe
❑ If asymptomatic no debridement, else consider surgical consultation
 
 
 
 
 
 
 
 
 
 
 
Prompt surgical consultation (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CBC: Complete blood count; CECT: Contrast-enhanced computed tomography; CT: Computed tomography; ERCP: Endoscopic retrograde cholangiopancreatography; EU: Endoscopic ultrasound; FNA: Fine-needle aspiration; GGT: Gamma-glutamyl transpeptidase; ICU: Intensive care unit; IV: Intravenous; MRCP: Magnetic resonance cholangiopancreatography; MRI: Magnetic resonance imaging; Q8h: Every 8 hours; Q12h: Every 12 hours

Modified Marshall Scoring System

Modified Marshall Scoring System
Organ System 0 1 2 3 4
Respiratory
PaO2/FiO2
>400 301-400 201-300 101-200 ≤101
Renal
Creatinine (μmol/l)
Creatinine (mg/dl)
≤134
<1.4
134-169
1.4-1.8
170-310
1.9-3.6
311-439
3.6-4.9
>439
>4.9
Cardiovascular
Systolic Blood Pressure (mmHg)
>90 <90, fluid responsive <90, not fluid responsive <90, pH <7.3 <90, pH <7.2

A score of 2 or more in any system defines the presence of organ failure.
A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.

For non-ventilated patients, the FiO2 can be estimated from below:

Supplemental oxygen (l/min) FiO2 (%)
Room air 21
2 25
4 30
6–8 40
9–10 50

Grades of Severity

The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.[1]

  • Mild acute pancreatitis
▸ No organ failure
▸ No local or systemic complications
  • Moderately severe acute pancreatitis
▸ Organ failure that resolves within 48 h (transient organ failure) and/or
▸ Local or systemic complications without persistent organ failure
  • Severe acute pancreatitis
▸ Persistent organ failure (>48 h)
– Single organ failure
– Multiple organ failure

Do's

  • Patients who fail to improve clinically (e.g., persistent abdominal pain, fever, nausea, unable to begin oral intake) within the first 48-72 h after admission.
  • Patients in whom the diagnosis is unclear.

Dont's

References

  1. 1.0 1.1 Banks, PA.; Bollen, TL.; Dervenis, C.; Gooszen, HG.; Johnson, CD.; Sarr, MG.; Tsiotos, GG.; Vege, SS.; Acosta, JM. (2013). "Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus". Gut. 62 (1): 102–11. doi:10.1136/gutjnl-2012-302779. PMID 23100216. Unknown parameter |month= ignored (help)
  2. Yang, AL.; Vadhavkar, S.; Singh, G.; Omary, MB. (2008). "Epidemiology of alcohol-related liver and pancreatic disease in the United States". Arch Intern Med. 168 (6): 649–56. doi:10.1001/archinte.168.6.649. PMID 18362258. Unknown parameter |month= ignored (help)
  3. Forsmark, CE.; Baillie, J. (2007). "AGA Institute technical review on acute pancreatitis". Gastroenterology. 132 (5): 2022–44. doi:10.1053/j.gastro.2007.03.065. PMID 17484894. Unknown parameter |month= ignored (help)
  4. Fortson, MR.; Freedman, SN.; Webster, PD. (1995). "Clinical assessment of hyperlipidemic pancreatitis". Am J Gastroenterol. 90 (12): 2134–9. PMID 8540502. Unknown parameter |month= ignored (help)
  5. Yi, GC.; Yoon, KH.; Hwang, JB. (2012). "Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease". Pediatr Gastroenterol Hepatol Nutr. 15 (4): 272–5. doi:10.5223/pghn.2012.15.4.272. PMID 24010098. Unknown parameter |month= ignored (help)
  6. Köhler, H.; Lankisch, PG. (1987). "Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma". Pancreas. 2 (1): 117–9. PMID 2437571.
  7. Tenner, S.; Baillie, J.; DeWitt, J.; Vege, SS. (2013). "American College of Gastroenterology guideline: management of acute pancreatitis". Am J Gastroenterol. 108 (9): 1400–15, 1416. doi:10.1038/ajg.2013.218. PMID 23896955. Unknown parameter |month= ignored (help)
  8. Arvanitakis, M.; Delhaye, M.; De Maertelaere, V.; Bali, M.; Winant, C.; Coppens, E.; Jeanmart, J.; Zalcman, M.; Van Gansbeke, D. (2004). "Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis". Gastroenterology. 126 (3): 715–23. PMID 14988825. Unknown parameter |month= ignored (help)
  9. Zaheer, A.; Singh, VK.; Qureshi, RO.; Fishman, EK. (2013). "The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines". Abdom Imaging. 38 (1): 125–36. doi:10.1007/s00261-012-9908-0. PMID 22584543. Unknown parameter |month= ignored (help)
  10. Bollen, TL.; Singh, VK.; Maurer, R.; Repas, K.; van Es, HW.; Banks, PA.; Mortele, KJ. (2011). "Comparative evaluation of the modified CT severity index and CT severity index in assessing severity of acute pancreatitis". AJR Am J Roentgenol. 197 (2): 386–92. doi:10.2214/AJR.09.4025. PMID 21785084. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources